Total Payments
$15,837
2024 Payments
$2,067
Companies
30
Transactions
424
Medicare Patients
256
Medicare Billing
$47,165
Payment Breakdown by Category
Food & Beverage$11,562 (73.0%)
Research$3,239 (20.5%)
Travel$912.86 (5.8%)
Education$123.81 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,562 | 410 | 73.0% |
| Unspecified | $3,239 | 6 | 20.5% |
| Travel and Lodging | $912.86 | 5 | 5.8% |
| Education | $123.81 | 3 | 0.8% |
Payments by Type
General
$12,598
418 transactions
Research
$3,239
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $3,390 | 92 | $0 (2024) |
| Eli Lilly and Company | $2,762 | 2 | $0 (2018) |
| Sunovion Pharmaceuticals Inc. | $2,071 | 131 | $0 (2022) |
| Eisai Inc. | $1,239 | 14 | $0 (2017) |
| Allergan, Inc. | $1,008 | 45 | $0 (2020) |
| Axsome Therapeutics, Inc. | $716.18 | 17 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $530.05 | 11 | $0 (2023) |
| Shire North American Group Inc | $480.36 | 18 | $0 (2019) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $476.45 | 4 | $0 (2018) |
| Janssen Pharmaceuticals, Inc | $474.45 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,067 | 55 | ABBVIE INC. ($811.67) |
| 2023 | $1,916 | 50 | ABBVIE INC. ($1,090) |
| 2022 | $1,190 | 32 | ABBVIE INC. ($448.15) |
| 2021 | $1,749 | 56 | AbbVie Inc. ($1,040) |
| 2020 | $725.03 | 44 | Sunovion Pharmaceuticals Inc. ($338.02) |
| 2019 | $1,561 | 70 | Sunovion Pharmaceuticals Inc. ($548.66) |
| 2018 | $4,407 | 65 | Eli Lilly and Company ($2,624) |
| 2017 | $2,221 | 52 | Eisai Inc. ($1,239) |
All Payment Transactions
424 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $33.87 | General |
| Category: Psychology/Psychiatric | ||||||
| 12/06/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: Neuroscience | ||||||
| 11/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.82 | General |
| Category: NEUROSCIENCE | ||||||
| 11/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: NEUROSCIENCE | ||||||
| 11/08/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $22.61 | General |
| Category: Neuroscience | ||||||
| 11/07/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $21.15 | General |
| Category: ANTI-ANXIETY | ||||||
| 11/06/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $22.55 | General |
| Category: Psychology/Psychiatric | ||||||
| 10/25/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $21.68 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 10/24/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Psychology/Psychiatric | ||||||
| 10/24/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $25.13 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/24/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/24/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 10/23/2024 | Almatica Pharma LLC | LOREEV XR (Drug) | Food and Beverage | In-kind items and services | $19.76 | General |
| Category: ANTI-ANXIETY | ||||||
| 10/09/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $28.97 | General |
| Category: Psychology/Psychiatric | ||||||
| 10/09/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $1.88 | General |
| Category: Psychology/Psychiatric | ||||||
| 09/13/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.91 | General |
| Category: NEUROSCIENCE | ||||||
| 09/11/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $19.21 | General |
| 09/11/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.97 | General |
| Category: NEUROSCIENCE | ||||||
| 08/16/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $24.05 | General |
| Category: Psychology/Psychiatric | ||||||
| 08/13/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $124.97 | General |
| Category: NEUROSCIENCE | ||||||
| 07/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.72 | General |
| Category: NEUROSCIENCE | ||||||
| 07/03/2024 | Janssen Pharmaceuticals, Inc | INVEGA SUSTENNA (Drug) | Food and Beverage | In-kind items and services | $15.59 | General |
| Category: Neuroscience | ||||||
| 07/02/2024 | Supernus Pharmaceuticals, Inc. | Qelbree (Drug) | Food and Beverage | In-kind items and services | $14.13 | General |
| Category: VILOXAZINE HYDROCHLORIDE | ||||||
| 06/26/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: Psychology/Psychiatric | ||||||
| 06/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY | Eli Lilly and Company | $2,624 | 1 |
| A PHASE 3, 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 2-ARM, FIXED-DOSE TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BREXPIPRAZOLE OPC34712 IN THE TREATMENT OF SUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA OF THE ALZHEIMERS TYPE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $476.45 | 4 |
| A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY | Eli Lilly and Company | $138.40 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 68 | 167 | $36,425 | $11,662 |
| 2022 | 3 | 70 | 203 | $45,025 | $14,100 |
| 2021 | 3 | 61 | 154 | $33,700 | $11,171 |
| 2020 | 3 | 57 | 167 | $35,900 | $10,232 |
Total Patients
256
Total Services
691
Medicare Billing
$47,165
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 22 | 57 | $8,550 | $4,088 | 47.8% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 23 | 69 | $20,700 | $3,838 | 18.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 23 | 41 | $7,175 | $3,737 | 52.1% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 22 | 89 | $26,700 | $4,939 | 18.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 24 | 65 | $9,750 | $4,705 | 48.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 49 | $8,575 | $4,457 | 52.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 24 | 65 | $9,750 | $4,831 | 49.5% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 21 | 67 | $20,100 | $3,917 | 19.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 16 | 22 | $3,850 | $2,423 | 62.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 25 | 73 | $10,950 | $4,089 | 37.3% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 19 | 68 | $20,400 | $3,903 | 19.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 13 | 26 | $4,550 | $2,239 | 49.2% |
About Evelyn Lopez-Brignoni, MD, PA
Evelyn Lopez-Brignoni, MD, PA is a Child & Adolescent Psychiatry healthcare provider based in Coral Gables, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/12/2007. The National Provider Identifier (NPI) number assigned to this provider is 1306060256.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Evelyn Lopez-Brignoni, MD, PA has received a total of $15,837 in payments from pharmaceutical and medical device companies, with $2,067 received in 2024. These payments were reported across 424 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($11,562).
As a Medicare-enrolled provider, Lopez-Brignoni has provided services to 256 Medicare beneficiaries, totaling 691 services with total Medicare billing of $47,165. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Child & Adolescent Psychiatry
- Other Specialties Psychiatry
- Location Coral Gables, FL
- Active Since 04/12/2007
- Last Updated 09/12/2025
- Taxonomy Code 2084P0804X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1306060256
Products in Payments
- VRAYLAR (Drug) $4,380
- LATUDA (Drug) $2,071
- Auvelity (Drug) $716.18
- GEODON (Drug) $441.76
- AUSTEDO (Drug) $405.24
- TRINTELLIX (Drug) $386.86
- MYDAYIS (Drug) $336.84
- REXULTI (Drug) $325.80
- Azstarys (Drug) $325.49
- INVEGA SUSTENNA (Drug) $243.91
- SPRAVATO (Drug) $230.54
- CAPLYTA (Drug) $220.20
- Qelbree (Drug) $200.05
- VYVANSE (Drug) $166.48
- UZEDY (Drug) $124.81
- QUVIVIQ (Drug) $116.50
- ABILIFY ASIMTUFII (Drug) $111.72
- LOREEV XR (Drug) $85.85
- BRINTELLIX (Drug) $76.13
- Dyanavel XR (Drug) $52.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Child & Adolescent Psychiatry Doctors in Coral Gables
Lino Fernandez, Md, MD
Child & Adolescent Psychiatry — Payments: $2,411
Child & Adolescent Psychiatry $2,411
Jorge Hernandez, M.d, M.D
Child & Adolescent Psychiatry — Payments: $1,563
Child & Adolescent Psychiatry $1,563
Dr. Thomas Hunter, M.d, M.D
Child & Adolescent Psychiatry — Payments: $57.92
Child & Adolescent Psychiatry $57.92
Diana Antia, M.d, M.D
Child & Adolescent Psychiatry — Payments: $51.72
Child & Adolescent Psychiatry $51.72
Dr. Eugenio Rothe, Md, MD
Child & Adolescent Psychiatry
Child & Adolescent Psychiatry
Dr. Douglas Feltman, M.d, M.D
Child & Adolescent Psychiatry
Child & Adolescent Psychiatry